Immix Biopharma, Inc.

Immix Biopharma (IMMX) shows no cyber incidents or red-flag 8-K filings detected in our 90-day monitoring window, indicating operational stability over this period. However, absence of recent signals does not eliminate underlying risk—the company's financing history, equity dilution trajectory, and AI-detected risk patterns require deeper analysis. Our 90-day window is inherently narrow; biotech companies often face material developments on longer cycles. The full $49 Report extends to 12 months of history, calculates dilution risk scores, contextualizes all 8-K activity, and applies AI risk signal detection across capital structure and insider behavior.